Solarea Bio Announces First Close of Series B Financing Round
CAMBRIDGE, Mass. , /PRNewswire/ — Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health, announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.
Read More from the Global Wellness News ™